In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN demonstrated the most optimal effect for glaucoma over other cannabinoids.
InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021
InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021.
February 18, 2021
